Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 12:27 AM
Ignite Modification Date:
2025-12-25 @ 12:27 AM
NCT ID:
NCT06154967
Brief Summary:
The goal of this clinical trial is to learn about in describe participant population. The main questions it aims to answer are:
the outcomes of the efficacy (ORR) and safety (adverse events, including irAEs, AE, SAEs, and laboratory indicators) of continued immunotherapy in patients with immune-resistant IIIc/IV metastatic NSCLC treated with immune-induced radiotherapy (SBRT).
Participants will be asked to accept the treatment of ICIs regimen and SBRT plan as follows:
ICIs regimen: tislelizumab 200mg every 3 weeks, the first dose was given 7 days after the last SBRT treatment, then the first day of each cycle, 21 days as a cycle until disease progression.
SBRT plan: The radiation dose and fractionation of SBRT should be evaluated according to the size and location of the tumor.
Study:
NCT06154967
Study Brief:
Protocol Section:
NCT06154967